Iteria Biopharma — Seed · €5M

Iteria Biopharma, a GalChimia spin-out developing treatments for advanced metastatic cancers, closed a €5M seed round led by Inveready through Inveready Biotech IV, with Xesgalicia and existing shareholders. Funds will complete preclinical work on ITR-251 for metastatic castration-resistant prostate cancer and start Phase 1 trials in early 2027.